3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Sarcoma
2
Head & Neck
2
Breast
2
Thoracic
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Colorectal Neoplasms
16
Carcinoma, Hepatocellular
12
Pancreatic Neoplasms
11
Colonic Neoplasms
6
Rectal Neoplasms
5
Neoplasm Metastasis
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Cholangiocarcinoma
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Multiple Myeloma
2
Melanoma
2
Hematologic Neoplasms
2
Gallbladder Neoplasms
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Vulvar Neoplasms
1
Virus Diseases
1
Vaginal Neoplasms
1
Turcot syndrome
1
Interventions
pembrolizumab
25
Nivolumab
20
atezolizumab
8
Magnetic Resonance Spectroscopy
7
Ipilimumab
7
Specimen Handling
5
Paclitaxel
5
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Carboplatin
4
fludarabine
3
durvalumab
3
avelumab
3
Interleukin-2
3
Gemcitabine
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
tislelizumab
2
spartalizumab
2
regorafenib
2
epacadostat
2
cabozantinib
2
aldesleukin
2
Taxes
2
Pemetrexed
2
FAPI-46
2
Cisplatin
2
Albumin-Bound Paclitaxel
2
zanidatamab
1
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Immunoglobulin G
×
Gastrointestinal
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled